Background: In patients with advanced-stage III/IV follicular lymphoma (FL), there are many treatment options available. The current challenge is to choose the optimal strategy for the individual patient.
Methods: The literature was reviewed with respect to treatment strategies in patients with advanced FL by screening the PubMed databank.
Results: In advanced-stage III/IV FL, median survival may approach 8-10 years. Treatment strategies include a watch-and-wait strategy, chemoimmunotherapy, monotherapy with rituximab, and - as an experimental approach so far - radioimmunotherapy. The use of autologous hematopoietic stem cell transplantation (HSCT) for patients in first remission or chemosensitive relapse prolongs progression-free survival while the effect on overall survival remains unclear compared to standard chemotherapy. However, long-term results are flawed by high relapse rates and risk of secondary malignancies. In patients with relapsed/chemoresistant disease, allogeneic HSCT constitutes the only curative approach but is associated with high treatment-related mortality. In the palliative setting, low-dose involved-field irradiation constitutes an effective treatment option in order to control local symptoms with potential long-lasting response.
Conclusion: In case of advanced-disease FL, asymptomatic patients can be managed expectantly. In symptomatic patients, chemoimmunotherapy is regarded as standard therapy. In symptomatic elderly patients with relevant comorbidities, rituximab +/- single-agent chemotherapy, or low-dose involved-field radiotherapy might be appropriate. For younger patients with chemoresistant/relapsed disease, allogeneic HSCT might be considered, since advances in supportive care and better patient selection have resulted in improved outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00066-010-2091-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Analysis of Clinical and Radiologic Staging of Cervical Cancer: A Cross-Sectional Study in Ethiopia.
Ethiop J Health Sci
October 2024
Department of Radiology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Cervical cancer remains a significant challenge in developing countries, with many patients diagnosed at advanced stages. The clinical staging of cervical cancer is guided by the International Federation of Obstetrics and Gynecology (FIGO) guidelines, while computed tomography (CT) and magnetic resonance imaging (MRI) offer valuable supplemental information. This study aimed to evaluate the initial clinical and imaging stages of cervical cancer and to assess the agreement between these staging methods.
View Article and Find Full Text PDFMismatch repair, p53, and L1 cell adhesion molecule status influence the response to chemotherapy in advanced and recurrent endometrial cancer.
BMC Cancer
December 2024
Department of Obstetrics and Gynecology, Institution of Women's Medical Life Science, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Korea.
Objective: This study aimed to identify the recurrence and survival rates according to the mismatch repair (MMR), p53, and L1 cell adhesion molecule (L1CAM) status in patients with advanced and recurrent endometrial cancer (EC) receiving systemic chemotherapy.
Methods: This single-center retrospective cohort study included chemotherapy-naïve patients with advanced-stage (III/IV) or recurrent EC between January 2015 and June 2022 (n = 156), who were administered chemotherapy as adjuvant therapy or first-line palliative treatment. MMR and p53 status were assessed, and L1CAM was tested using immunohistochemistry in the p53-wild and MMR-proficient (p53wt/pMMR) group.
The pervasive impact of frailty on ovarian cancer care and the role of prehabilitation: Qualitative perspectives of key stakeholders.
J Geriatr Oncol
December 2024
Dana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Introduction: We performed a qualitative study to explore key stakeholders' perspectives about the impact of frailty on ovarian cancer care and evaluate a candidate prehabilitation intervention.
Materials And Methods: We conducted semi-structured interviews with patient-caregiver dyads and multi-disciplinary clinicians. Patients were ≥ 50 years of age with a new diagnosis of advanced stage (III/IV) ovarian cancer who received cancer-directed treatment (chemotherapy and/or surgery) during the past year and met criteria as pre-frail or frail using the FRAIL scale.
Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
Eur J Cancer
January 2025
Digestive Surgery, European Institute of Oncology IRCCS, Via Giuseppe Ripamonti, 435, Milan 20141, Italy. Electronic address:
Article Synopsis
- There has been a concerning rise in early-onset colorectal cancer (EO-CRC) cases, prompting research into how prognosis compares to late-onset colorectal cancer (LO-CRC).
- A systematic review of 26 studies found that EO-CRC patients are more likely to be diagnosed at advanced stages, yet they have better overall survival rates compared to LO-CRC patients, while other survival metrics like cancer-specific survival remain similar.
- The study highlights the need for better early detection methods for EO-CRC due to the differences in stage at diagnosis between the two groups.
Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0).
Clin Infect Dis
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Article Synopsis
- This study assessed the occurrence of invasive fungal disease (IFD) in patients who received allogeneic stem cell transplants in China during 2021.
- A total of 2015 patients were involved, with 76% receiving mold-active antifungal prophylaxis, yet the cumulative incidence of IFD was found to be 6.3% within a year post-transplant.
- Key risk factors for IFD included advanced disease stages, delayed engraftment of neutrophils and platelets, and severe graft-versus-host disease, contributing to an IFD-related mortality rate of 48.28%.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!